These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. Cheong YH; Kim MK; Son MH; Kaang BK Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947 [TBL] [Abstract][Full Text] [Related]
5. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM J Pharmacol Exp Ther; 2015 Apr; 353(1):52-63. PubMed ID: 25630467 [TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Harikumar KG; Wootten D; Pinon DI; Koole C; Ball AM; Furness SG; Graham B; Dong M; Christopoulos A; Miller LJ; Sexton PM Proc Natl Acad Sci U S A; 2012 Nov; 109(45):18607-12. PubMed ID: 23091034 [TBL] [Abstract][Full Text] [Related]
7. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. Morris LC; Days EL; Turney M; Mi D; Lindsley CW; Weaver CD; Niswender KD J Biomol Screen; 2014 Jul; 19(6):847-58. PubMed ID: 24525870 [TBL] [Abstract][Full Text] [Related]
8. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide. Nakane A; Gotoh Y; Ichihara J; Nagata H Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912 [TBL] [Abstract][Full Text] [Related]
10. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772 [TBL] [Abstract][Full Text] [Related]
11. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618 [TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Wootten D; Savage EE; Valant C; May LT; Sloop KW; Ficorilli J; Showalter AD; Willard FS; Christopoulos A; Sexton PM Mol Pharmacol; 2012 Aug; 82(2):281-90. PubMed ID: 22576254 [TBL] [Abstract][Full Text] [Related]
13. A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nolte WM; Fortin JP; Stevens BD; Aspnes GE; Griffith DA; Hoth LR; Ruggeri RB; Mathiowetz AM; Limberakis C; Hepworth D; Carpino PA Nat Chem Biol; 2014 Aug; 10(8):629-31. PubMed ID: 24997604 [TBL] [Abstract][Full Text] [Related]
14. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Beinborn M; Worrall CI; McBride EW; Kopin AS Regul Pept; 2005 Aug; 130(1-2):1-6. PubMed ID: 15975668 [TBL] [Abstract][Full Text] [Related]
15. Small molecule drug discovery at the glucagon-like peptide-1 receptor. Willard FS; Bueno AB; Sloop KW Exp Diabetes Res; 2012; 2012():709893. PubMed ID: 22611375 [TBL] [Abstract][Full Text] [Related]
16. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5211-6. PubMed ID: 23479653 [TBL] [Abstract][Full Text] [Related]
17. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Ban K; Noyan-Ashraf MH; Hoefer J; Bolz SS; Drucker DJ; Husain M Circulation; 2008 May; 117(18):2340-50. PubMed ID: 18427132 [TBL] [Abstract][Full Text] [Related]
18. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Koole C; Wootten D; Simms J; Valant C; Miller LJ; Christopoulos A; Sexton PM Mol Pharmacol; 2011 Sep; 80(3):486-97. PubMed ID: 21616920 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Marzioni M; Alpini G; Saccomanno S; Candelaresi C; Venter J; Rychlicki C; Fava G; Francis H; Trozzi L; Glaser S; Benedetti A Gastroenterology; 2007 Jul; 133(1):244-55. PubMed ID: 17631146 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]